Back to top

Altimmune initiates PERFORMA trial

Altimmune (ALT) announced that the company has begun enrolling patients in the PERFORMA Phase 3 trial evaluating the efficacy and safety of pemvidu...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Altimmune, Inc. (ALT)